Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive

NCT07712029 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Advanced Refractory Solid Tumors
EGFR Gene Overexpression

Interventions

DRUG: Becotatug Vedotin
DRUG: Pucotenlimab

Sponsor

Tianjin Medical University Second Hospital

Collaborators

[object Object]